Korro Bio的领先RNA编辑药物KRRO-110在针对α1-抗胰蛋白酶缺乏症(AATD)的I/II期试验中未能达到预期疗效,导致公司放弃该项目。公司宣布裁减34%的员工(约50人),预计产生240万美元的重组费用,作为战略调整的一部分,以重新分配资源。诺和诺德与Korro的合作协议暂停一年,用于重新评估伙伴关系。公告后,Korro Bio股价暴跌近80%,市值大幅缩水;多家投行下调评级。11...
Source LinkKorro Bio的领先RNA编辑药物KRRO-110在针对α1-抗胰蛋白酶缺乏症(AATD)的I/II期试验中未能达到预期疗效,导致公司放弃该项目。公司宣布裁减34%的员工(约50人),预计产生240万美元的重组费用,作为战略调整的一部分,以重新分配资源。诺和诺德与Korro的合作协议暂停一年,用于重新评估伙伴关系。公告后,Korro Bio股价暴跌近80%,市值大幅缩水;多家投行下调评级。11...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.